Porcine Reproductive and Respiratory Syndrome vaccine virus
AssigneesElanco UK AH Limited, Elanco US Inc.
InventorsStephen Qitu Wu, Cinta Prieto Suarez, Geoffrey Gregory Labarque
Life of this patent
Estimating the term…
Abstract
The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.
Claims20
A modified, live Porcine Reproductive and Respiratory Syndrome (PRRS) virus strain, wherein the consensus complementary DNA sequence of said PRRS strain is at least 95% identical to a sequence selected from the group consisting of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, and SEQ ID NO:
- 4.
An immunogenic composition comprising a modified, live PRRS virus strain having a consensus complementary DNA sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, and SEQ ID NO:
- 4, and a pharmaceutically-acceptable excipient, stabilizer, solubilizer, or diluent.
A vaccine comprising a modified, live PRRS virus strain, wherein said PRRS virus strain is a DE 14-3073 strain designated PTA-125490;
- an ES 13-49strain designated PTA-125489;
- an IT 14-32 strain designated PTA-125488, or a PL 14-02 strain designated PTA-125487.
Dependencies are inferred from the claim text.